<scp>SYHA1813</scp> , A <scp>VEGFR</scp> and <scp>CSF1R</scp> Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study
Authors
Zhengwen He (ORCID: https://orcid.org/0000-0002-4180-1053)
Tao Sun (ORCID: https://orcid.org/0000-0002-8962-2193)
Zhuang Kang (ORCID: https://orcid.org/0000-0002-8449-644X)
Liang Wang (ORCID: https://orcid.org/0000-0002-4052-1316)
Annals of Clinical and Translational NeurologyVol. 12(11)
Institutions
Nanchang University (CN), Capital Medical University (CN), Fudan University (CN), Wuhan University (CN), Beijing Tian Tan Hospital (CN), Hunan Cancer Hospital (CN), Renmin Hospital of Wuhan University (CN), Henan Cancer Hospital (CN), Shijiazhuang Yiling Pharmaceutical (China) (CN), Tang Du Hospital (CN), Huashan Hospital (CN), Tongji Hospital (CN), Liaoning Cancer Hospital & Institute (CN), First Affiliated Hospital of Nanchang University (CN), CSPC Pharmaceutical Group (CN), Huazhong University of Science and Technology (CN)